Genetic blueprint of Sjögren's disease opens door to targeted therapies

A comprehensive review of the genetic and epigenetic drivers of primary Sjögren syndrome reveals new therapeutic targets for this debilitating autoimmune disorder affecting millions globally. The findings could accelerate development of precision treatments, reducing reliance on generalized immunosuppressants and improving outcomes for patients with limited current options.

Originaltitel: Genetics and epigenetics of primary Sjogren syndrome: implications for future therapies